Posters

Pharmacotherapy of primary open-angle glaucoma: focusing on patients’ quality of life

Poster Details

First Author: O.Kryvoviaz UKRAINE

Co Author(s):    S. Kryvoviaz   Y. Tomashevska                 

Abstract Details

Purpose:

The aim of treatment patients with primary open-angle glaucoma (POAG) is to stop the progression of the disease. The evidence of high effective treatment is maintaining sufficient quality of life (QoL) by the means of pharmacotherapy measures. Therefore, the purpose of the research is to analyze the ways of studying the integral indicator "quality of life" for the patients with glaucoma and explore the effect of pharmacotherapy on the patients’ QoL.

Setting:

247 patients (120 female and 127 male) with POAG participated in the trial, who were on dispensary registration in medical institutions of Vinnytsia region (Ukraine): 68 patients with the 1st stage of disease, 83 with the 2nd, 61 with the 3rd and 35 patients with the 4th POAG stage.

Methods:

We have developed a questionnaire containing 39 questions, grouped into five sections to define the patients’ age, sex, place of residence, the stage of the disease, the range of prescribed medicines, the patients’ QoL and the compliance. The integral indicator QoL has been calculated in points for each patient with POAG. It included a functional state (working capacity, exercise tolerance, performance of household functions), symptoms of the disease, mental state of the patient, social activity, degree of satisfaction with medical aid. These parameters were subsequently grouped, and the mean has been defined for each of the pharmacotherapy scheme used.

Results:

The evaluation of treatment results obtained from conducted questionnaire made it possible to calculate the QoL indicators ranking from 60 to 172 points, on average 111,91 ± 17,46. The direct dependence of the QoL indicator on the degree of progression of the disease has been defined. 59 treatment schemes were administered to patients with POAG. A detailed analysis was subjected to 8 schemes that were prescribed most frequently. The highest values of all QoL indicators were noted by patients taking Lanotan (Latanoprost) (132,33±27,26 points), the lowest – Arutimol (Timolol) 0,5% combined with Taflotan (Tafluprost) (99,77±12,67 points).

Conclusions:

The concept QoL is the main criterion for the therapy effectiveness in "value-benefit" analysis in pharmacoeconomic studies. The method used to evaluate the patients’ with POAG QoL made it possible to analyze the nature of the disease impact on the vital activity and also was used as a criterion for assessing the effectiveness of pharmacotherapy in order to find expediency and cost effectiveness of antiglaucoma drugs. The results of the conducted research of the pharmacotherapy features and medical arrangement of patients with POAG are the basis for determining the priority direction of healthcare optimization for the studied group of patients.

Financial Disclosure:

None